References
- Kanavos P, van den Aardweg S, Schurer W. Diabetes expenditure, burden of disease and management in 5 EU countries. London: LSE Health, London School of Economics, 2012
- Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96
- Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193-203
- Malanda UL, Welschen LM, Riphagen II, et al. Self-monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev 2012;1:CD005060
- Yeaw J, Lee WC, Aagren M, et al. Cost of self-monitoring of blood glucose in the United States among patients on an insulin regimen for diabetes. J Manag Care Pharm 2012;18:21-32
- Charbonnel B, Penfornis A, Varroud-Vial M, et al. Insulin therapy for diabetes mellitus: treatment regimens and associated costs. Diabetes Metab 2012;38:156-63
- Guelfucci F, Clay E, Aballea S, et al. Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France. BMC Endocr Disord 2013;13:15
- Liebl A, Breitscheidel L, Nicolay C, et al. Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study. Curr Med Res Opin 2008;24:2349-58
- von Ferber L, Koster I, Hauner H. Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM study. Medizinische Klinik 2006;101:384-93
- Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
- Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65
- Organization for Economic Cooperation and Development. OECD.stat (database). Available at: http://stats.oecd.org/viewhtml.aspx?datasetcode=AV_AN_WAGE&lang=en#
- European Foundation for the Improvement of Living and Working Conditions. Developments in collectively agreed working time 2013. Dublin, Ireland: European Foundation for the Improvement of Living and Working Conditions, 2014
- Williams A, Lloyd A, Watson L, et al. Cost of scheduled and unscheduled asthma management in seven European Union countries. Eur Respir Rev 2006;15:4
- Jönsson B; CODE-2 Advisory Board. Revealing the cost of type 2 diabetes in Europe. Diabetologia 2002;45:S5-S12
- Antoñanzas F, Brenes F, Molero JM, et al. Coste-efectividad de la combinación dutasterida y tamsulosina en el tratamiento de la hiperplasia benigna de próstata en Espña. Actas Urológicas Españolas 2011;35:65-71
- Instituto Nacional de la Salud. Resultados de la gestión analítica en los hospitales del INSALUD GECLIF 2000. Subdirección General de Coordinación Administrativa. Madrid: Instituto Nacional de la Salud, 2001
- Hernández-Pastor LJ, Ortega A, Garcia-Layana A, et al. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration. Clin Ther 2008;30:2436-51
- San Millán-San Pedro CH. Oblikue: Nota interior. Tarifas por servicios sanitarios prestados a particulares. 2002
- Curtis L. Unit costs of health and social care 2013. Cantebury, UK: Personal Social Services Research Unit, 2013
- Bevan M. Reference NHS. Computer Software. 2013. Available at: https://itunes.apple.com/gb/app/nhs-reference/id335643807
- Department of Health. NHS reference costs 2012–2013. 2013. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/261154/nhs_reference_costs_2012-13_acc.pdf [Last accessed 25 August 2015]
- Eurostat. HICP – inflation rate. Available at: http://ec.europa.eu/eurostat/tgm/table.do?tab=table&init=1&language=en&pcode=tec00118&plugin=1
- Brown JB, Nichols GA, Glauber HS, et al. Health care costs associated with escalation of drug treatment in type 2 diabetes mellitus. Am J Health Syst Pharm 2001;58:151-7
- Rosenblum MS, Kane MP. Analysis of cost and utilization of health care services before and after initiation of insulin therapy in patients with type 2 diabetes mellitus. J Manag Care Pharm 2003;9:309-16
- Organization for Economic Cooperation and Development. Educational attainment and labour-force status. 2014. Available at: OECD.Stat.org [Last accessed 13 July 2016]